Market Place
Sourcing Support
Anavex Life`s Acceptance of Blarcamesine Phase IIb/III Data Manuscript
25 Nov 2024 //
GLOBENEWSWIRE
NANOBIOTIX to Attend Investor Conferences in November
31 Oct 2024 //
GLOBENEWSWIRE
Anavex Presents ANAVEX®2-73 Biomarker Data In Fragile X Syndrome
30 Jul 2024 //
GLOBENEWSWIRE
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine
08 Jan 2024 //
GLOBENEWSWIRE
Anavex’s experimental drug fails Rett syndrome study, stock falls
03 Jan 2024 //
ENDPTS
Anavex Received Agreement from CHMP for Submission of a MAA of Oral Blarcamesine
19 Dec 2023 //
GLOBENEWSWIRE
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine
22 Nov 2023 //
GLOBENEWSWIRE
Anavex Initiates Regulatory Submission of Blarcamesine for Alzheimers Disease
20 Nov 2023 //
GLOBENEWSWIRE
Anavex`s Phase 2b/3 Trial of Blarcamesine Shows Robust Clinical Efficacy
14 Sep 2023 //
GLOBENEWSWIRE
Long-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX®2-73
28 Jun 2023 //
GLOBENEWSWIRE
Anavex Life Sciences Announces Completion of ANAVEX EXCELLENCE Phase 2/3 Trial
06 Jun 2023 //
GLOBENEWSWIRE
ANAVEX Announces Issuance of Property Compositions Patent for ANAVEX2-73
01 Jun 2023 //
GLOBENEWSWIRE
Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX
01 May 2023 //
GLOBENEWSWIRE
Anavex Announces Exceeding of Enrollment Target for the ANAVEX 2-73 EXCELLENCE Phase 2/3 Trial
02 Feb 2023 //
GLOBENEWSWIRE
Anavex (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints
01 Dec 2022 //
GLOBENEWSWIRE
Anavex Life Announces Late-Breaking Presentation of P 2b/3 Data of Oral ANAVEX®
17 Oct 2022 //
GLOBENEWSWIRE
Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73
21 Sep 2022 //
GLOBENEWSWIRE
Anavex Provides Supplemental Information on ANAVEX 2-73 Phase 3 Trial
04 Feb 2022 //
GLOBENEWSWIRE
After changing study goals, Anavex touts Rett syndrome win
02 Feb 2022 //
FIERCEBIOTECH
Anavex Life Sciences Announces Positive Data for ANAVEX®2-73
21 Jun 2021 //
GLOBENEWSWIRE
Anavex Reports New Publication in Medical Journal on Alzheimer`s Disease
14 Jun 2021 //
GLOBENEWSWIRE
Anavex Life Sciences Announces ANAVEX®2-73 Meets Primary and Secondary
15 Dec 2020 //
GLOBENEWSWIRE
Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application
30 Nov 2020 //
GLOBENEWSWIRE
Homology Medicines Announces Presentation of Positive Data from the Dose
06 Nov 2020 //
GLOBENEWSWIRE
Anavex Life Sciences Announces Positive Results Pha2 Trial ANAVEX®2-73
14 Oct 2020 //
GLOBENEWSWIRE
Anavex completes ANAVEX2-73 US phase 2 studies in Rett syndrome
11 Sep 2020 //
PHARMABIZ
Anavex completes mid-stage study of lead drug in rare brain development disorder
09 Sep 2020 //
SEEKINGALPHA
Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73
05 Aug 2020 //
PRESS RELEASE
Anavex starts dosing patients in Rett syndrome trial
02 Jul 2020 //
WWW.CLINICALTRIALSARENA
Anavex Life Sciences Announces 1st Patient in EXCELLENCE Ph 2/3 Trial
01 Jul 2020 //
GLOBENEWSWIRE
Anavex surpasses 50% of enrollment target of the ANAVEX2-73 phase 2 trial
17 Jun 2020 //
PHARMABIZ
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX
16 Jun 2020 //
GLOBENEWSWIRE
Anavex receives Health Canada & UK MHRA approvals to ph 2b/3 trial of ANAVEX2-73
07 Jun 2020 //
PHARMABIZ
Anavex Life Sciences Receives Regulatory Approval from UK MHRA 2b/3 ANAVEX®2-73
04 Jun 2020 //
GLOBENEWSWIRE
Anavex Life Sciences Announces Initiation of First-in-Human Ph 1 of ANAVEX®3-71
21 May 2020 //
GLOBENEWSWIRE
Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73
23 Apr 2020 //
GLOBENEWSWIRE
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73
24 Feb 2020 //
GLOBENEWSWIRE
Anavex Life Sciences Announces FTD Granted by U.S. FDA for ANAVEX®2-73
03 Feb 2020 //
GLOBENEWSWIRE
Anavex Life Sciences Announces Achievement of Enrollment Target the ANAVEX®2-73
27 Jan 2020 //
GLOBENEWSWIRE
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data
04 Dec 2019 //
BUSINESS WIRE
